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In the modern practice of Allergy, it is occasionally 
necessary or convenient to perform routine diagnostic skin testing 
while the patient is taking antihistamines. Current texts contain 
general statements that antihistamines depress skin reactions, but 
no quantitative data are given. Present concepts are based on work 
done with antigen challenge in sites locally injected with Pyri- 
benzamine or Benadryl.
A double blind study was designed to evaluate the effect 
of oral doses of antihistamine within the currently accepted 
therapeutic range. The patients studied included both reactors 
and nonreactors. The antihistamine utilized was Pyribenzamine, 
and a placebo was obtained for the fifty milligram tablet. Over 
seventy-five patients were challenged with two sets of ten intra- 
dermal injections, and results were tabulated before the double 
blind code was broken.
This study indicated the need for further study in the range 
of nonreactors and very strong reactors. Analysis demonstrated no 
significant effect of antihistamine on intradermal wheals.
Antihistamines may be used to suppress systemic effects of antigen 
challenge, while skin reactions serve as a guide to hyposensitiza­
tion therapy.
This abstract of about 177 words is approved as to form and 
content. I recommend its publication.
TABLE OF CONTENTS
CHAPTER PAGE
I. THE HISTORY OF MODERN ALLERGY .......................... 1 3
Early histamine research ............................... . 1
Role of skin testing in treatment of allergic patient . 
The use of skin testing to evaluate antihistaminic
. 3 1
activity ............................................ 4 3
A study devised to relate therapy with antihistamines 4
to clinical interpretation of skin tests . 5
II. TECHNIQUE ................................................ 6 6
Selection of patients ...................................
Method of giving drugs ............................... 6 7
Skin testing procedure ............................... . 7
III. RESULTS ..................................................... 9 8
Analysis of coarse d a t a ................. .... . 9
Graphic presentation of testing results . . . . . 10 9
IV. DISCUSSION ................................................
General trend seen in data .......................... . 25 :1
All skin reactions do not offer good basis for study . 25
Additional studies on selected drug forms . . . .  
Positive skin tests found in persons who had
*2. 26
no allergic history ................................... >3. 26
V. CONCLUSIONS ................................................ . 27
BIBLIOGRAPHY ..................................................... >4
LIST OF FIGURES
FIGURE PAGE
1. Controls and Antihistamine Groups Represented
Graphically . . . . .    11
2. Patients Receiving Placebo and Antihistamine,
Initial Reaction Z e r o ...........................................13
2a. Patients Receiving Single Drug, Initial Reaction Zero . . 14
3. Patients Receiving Placebo and Antihistamine,
Initial Reaction One P l u s ...................................... 16
3a. Patients Receiving Single Drug, Initial
Reaction One P l u s ...............................................17
4. Patients Receiving Placebo and Antihistamine,
Initial Reaction Two P l u s ..........................   18
4a. Patients Receiving Single Drug, Initial
Reaction Two P l u s ...............................................19
5. Patients Receiving Placebo and Antihistamine,
Initial Reaction Three Plus ............................... 21
5a. Patients Receiving Single Drug, Initial
Reaction Three P l u s .......................................... 22
6. Patients Receiving Placebo and Antihistamine,
Initial Reaction Four P l u s ................................. 23
6a. Patients Receiving Single Drug, Initial
Reaction Four P l u s ...................... 24
A STUDY OF THE EFFECT OF ANTIHISTAMINE ON CLINICAL 
ALLERGY SKIN TESTING
by James Glazebrook Billingsley, Captain, MC, U.S. Ariry 
Fitzsimons General Hospital, Denver, Colorado
CHAPTER I 
THE HISTORY OF MODERN ALLERGY
Man's reaction to his environment involves numerous complex 
systems all geared for survival. On occasion, one of the reaction 
systems fails to offer protection and actually becomes a deadly 
threat. Anaphylaxis involves such a reaction (14). The specialty 
of Allergy is based on the need to reduce untoward reactions of man 
to his world and, sometimes, to himself.
Not all allergic reactions are severe nor seem to represent 
hypersensitivity at a dangerous level. Physicians have studied this 
type of phenomenon and its symptoms for less than sixty years (20).
The first ten years of this century produced three different study 
approaches in Germany, France, and the United States. The basis for 
present-day allergy practice evolved in these schools (3, 11). By 
1909, the general framework for the theory of anaphylaxis was pro­
posed. At that time, Dale and Lardlawn implicated histamine as 
important in hypersensitivity reactions.
Early histamine research. Although it was soon recognized 
that histamine was not the only factor involved in allergic responses, 
the study of the pharmacology of this compound shed great light on 
the concept of anaphylaxis (11). Since histamine produced many of
the reactions of anaphylaxis (26, 1), Lewis and Grant were stimulated 
to look for the compound in actual states of allergic reaction. In 
1926, they reported the similarity of histamine wheals and the 
whealing reaction of dermographism, urticaria factitia, and food 
allergy (12).
From that knowledge, several centers concentrated a search 
for a satisfactory method of counteracting the histamine effect in 
allergic reactions in man. When histaminase and histamine desensiti­
zation failed, certain sympathomimetic compounds were investigated. 
Although many had limited promise, side effects far outweighed the 
benefits. Bovet and Staub reported in 1937 that phenolic ethers 
blocked certain of the actions of histamine. Initial use in animals 
proved the first compounds to be too toxic. Further study led to the 
synthesis of RP 2339, Antergan. The initial report of the successful 
clinical trial with this drug was made by Halpern and his group in 
1942. With this, the era of histamine antagonists or so-called 
antihistamines was opened in the field of Allergy (12).
Other compounds were soon developed which appeared to counter­
act many of the manifestations of anaphylaxis in man. Research 
demonstrated the ability to reduce whealing, capillary permeability, 
and bronchospasm caused by the injection of histamine (4). Clinical 
trial revealed varied effectiveness in reducing the clinical symptoms 
noted in anaphylaxis in humans. It is stressed that the very best of 
the antihistamines known today produces only limited protection and
symptomatic coverage in the treatment of allergic reactions. None 
offers a true basis for attacking the hypersensitivity problem at 
its source.
Role of skin testing in treatment of allergic patient.
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Although the newer compounds have reduced side effects and increased 
primary antihistamine activity, the only true present-day basis for 
treatment of allergy at a cause and effect level remains in the 
realm of hyposensitization to antigens responsible for symptoms.
Since the development of skin testing techniques and hyposensitiza­
tion therapy, no single approach has offered more specific or effec­
tive therapy in the hypersensitive state. Thus, skin testing remains 
important in the management of allergic disorders (20).
The history taken from the allergic patient will often outline 
the specific areas of an individual's hypersensitivity, and the use of 
skin testing procedures now serves as a guide to diagnosis and therapy. 
In 1912, Schloss clearly demonstrated the correlation between sensi­
tivity to egg and the positive skin test to the same protein. Further 
interest was generated when Clowes produced skin whealing in reaction 
to intradermal injection of extract of ragweed pollen. The total 
scope of testing procedures and techniques expanded quickly as Cooke 
and his group investigated the widening area of skin reactions and 
published their reports during 1915 and 1916 (8).
The use of skin testing to evaluate antihistaminic activity. 
Skin testing procedures were well established in clinical and 
investigative use when the first antihistamines were made clinically 
available. One of the earliest criteria for the use of antihistamine 
was based on its ability'to counteract skin whealing when introduced 
locally in the skin. Such techniques were even used as an early assay 
to determine the relative strengths or physiological potency of new 
antihistamines as they were introduced on the market (25).
Arbesman injected Pyribenzamine in serial dilutions intra- 
dermally into human subjects and followed, after an interval of 
forty-five minutes, with allergen challenge. Both in direct testing 
and in passive transfer, a generalized reduction in whealing was 
noted (4). Antihistamine ointment was rubbed into the local areas 
of testing and then allergens were injected (22). Other investigators 
used iontophoresis to introduce antihistamine through the epidermis 
prior to injection of test solutions (2, 24). Oral antihistamine in 
large doses appeared to have a similar depressive effect. Although 
little was known of the absorption, distribution, and true action of 
antihistamines, it was generally concluded that the drugs reduced 
whealing on human skin, if the concentration was high enough in the 
area where the allergens were introduced. Textbooks on Allergy still 
contain the caution that skin tests in the allergic patient are 
unreliable if the person has been on enough antihistamine to control 
symptoms (29). Doses used to depress the skin test reaction in early 
studies appeared to be quite high for therapeutic purposes. The
question arose concerning the possible reliability of skin tests done 
while the patient was using antihistamines for symptomatic control: 
was it really necessary to discard such tests as invalid?
A study devised to relate therapy with antihistamines to 
clinical interpretation of skin tests. With this question in mind, 
a double blind study was set up at Fitzsimons General Hospital in 
1957 to attempt to clarify this single point.
The antihistamine chosen was Pyribenzamine. Because of the 
interest in testing the depressive effect of therapeutic doses of 
this drug, a total of 200 mg. was given in four divided doses daily. 
This compound was one of those first investigated and is referred to 
frequently in the reports of skin testing made in the 1947-to-1952 
period (4, 14). Pyribenzamine is still considered one of the most j 
active of the clinically useful drugs and, thus, would correlate the 
early work with the clinical experience of today. Placebos* were 
obtained to control the double blind method as carefully as possible.
*The assistance of Ciba in making available placebos for 50 ir 
Pvribenzamine is sratefullv acknowledeed.
CHAPTER II
TECHNIQUE
Selection of patients. Patients were selected at random 
over a two and one-half year period at a rate to permit a single 
examiner to perform the entire testing procedure. There was a 
total of seventy-five patients tested during that length of time, 
each receiving at least two sets of skin tests. The patients 
tested were obtained, in most part, from the Allergy Clinic and 
were divided into three categories. The first group had received 
no previous skin tests other than screening by the staff of the 
clinic and was receiving no medication. The second group was on 
active hyposensitization therapy for symptoms of hay fever, urti­
caria, or asthma. The third group was being treated with measures 
other than injection therapy for the above conditions.
An additional group was made up of hospitalized patients 
with no history of allergy in themselves or in any of their close 
blood relatives. The separate analysis of this group produced some 
data which were as thought provoking as the entire study in itself.
Method of giving drugs. Patients were given eight pills 
coded and bottled by the pharmacy staff with the label, "Pyribenza- 
mine, one every six hours." Both placebo and antihistamine were 
packaged identically, and no attempt was made by the investigator 
to discover which was given. Additional instructions were given
each subject to insure that the final dose would be taken one hour 
prior to the time when skin tests were to be given. The only con­
trol of medication was an effort to insure that no patient be given 
the same bottle number twice.
Skin testing procedure. After the eighth dose (400 mg. of 
Pyribenzamine in forty-eight hours), the patient was tested with ten 
antigens selected from the following groups: pollens, inhalants,
molds, and foods. The patients with records of previous testings 
by the allergy staff received antigens which had produced signifi­
cant reactions.
After the technique was established with the aid of the 
allergy staff, all of the testing was done by the author. A uniform 
wheal size of 3 mm. was maintained. The outer aspect of the arm 
was used in all cases with both sets of intradermal wheals placed on 
the same area. Prior to testing, the area was prepared with alcohol 
sponging and thorough drying. The tests were read after twenty 
minutes and recorded as zero to four plus, as described by Sheldon (2 
Occasional duplicate readings were made by members of the Allergy 
Department staff in an added attempt to gain uniformity throughout 
the two and one-half year period during which the testing was accom­
plished. Each patient had a previously recorded negative test to 
rule out sensitivity to the diluent.
Each patient in the study received two separate sets of skin 
tests following two random courses of medication. In this manner, 
many of the patients acted as their own controls. When the code was 
broken at the completion of the study, the results were tabulated 
according to the drug which the patient had received.
In each patient representative antigens were given from severa] 
of the basic groups. Thus each patient was challenged with representat 
pollens, inhalants, molds, and occasionally foods. Over 80 different 
specific antigens were utilized, chosen when possible by earlier testir 
Over fifty tests were repeated to ragweed, ash, cat hair, house dust, i 
mold mix. Some antigens, such as mountain cedar, were used in only eij 
to ten patients.
CHAPTER III
RESULTS
Analysis of coarse data. Although interpretative data, as 
obtained by skin testing, does not lend itself to direct statistical 
evaluation, several methods were used to judge the results obtained 
in this study. Trend analysis, which is difficult to graphically 
present, did not show any significant alteration of the skin test, 
whether the patient was on antihistamine or placebo. Graphic 
analysis, as shown in Figures 1 through 6a, appeared to be the most 
satisfactory method of presenting the data.
The reactions are divided into two groups. The first group 
is comprised of those who were given both the placebo and the anti­
histamine in random order and represent patients acting as their own 
controls. This group received one set of tests following antihista­
mine and another set following placebo. They should demonstrate the 
antihistamine effect, if any was present. The second group is com­
prised of those who received either the placebo or the antihistamine 
prior to both series of intradermal tests. This group represents 
the patients who, for the purposes of evaluation, received no drug 
at all and serve as controls. They reflect reproducibility of the 
procedure used.
Graphic presentation of testing results. The graphs pre­
sented list the initial or placebo reactions at zero to four plus.
The number on each graph represents the total number of patient 
tests which reacted at each level, zero to four plus. The columns 
show how many of the second reactions were unchanged, increased, or 
decreased. Each graph represents the comparison between the first j
and second testing for each individual antigen. The graphs are £
arranged in pairs to facilitate comparison of the scatter seen in 
the control and antihistamine tests. t
In Figure 1, the three columns under the heading "Controls" 
present the data on 199 tests which were repeated following duplicate 
drugs. These data represent results obtained in control subjects.
The checkered center column reflects the 55% of tests to the dif­
ferent antigens which reacted at the same level when retested. The 
first, or solid black column, represents the 28% of tests which 
decreased on retesting. The striped column shows that 177» of the 
199 tests increased in reactivity when retested. This graph reflects
the reproducibility of the skin testing technique without any drug
effect, since control patients received the same drug prior to both 
test sets.
The three columns of figures labeled "Antihistamine" demon­
strate comparative data for tests done after antihistamines, con­
trasted with those done in the same subjects after placebo. Of 
661 pairs of tests, the center checkered column indicates that
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CONTROLS vs ANTIHISTAM INE ANALYZED AS A GROUP
CONTROLS ANTIHISTAMINE
Figure 1. Analysis of the two groups of patients showing 
per cent of tests which remained the same, increased, or decreased 
upon retesting.
507<> reacted at the same level following placebo and following anti­
histamine. Twenty-three per cent of the test reactions decreased, 
as represented by the solid black bar, and 2 7 reacted more strongly
on antihistamine than on placebo.
The distribution in these two groups portrays the information 
obtained by trend analysis--that the scatter of change in patients 
is as great when routinely retested as it is when they are tested 
with placebo and then with antihistamine.
Figures 2 through 6a reflect a breakdown of Figure 1 into 
graphs, representing each of the possible levels of reaction, from 
zero to four plus. Each pair of illustrations shows the changes 
shown by the antihistamine group in direct comparison with the same 
level of reactivity in tests done on the control subjects.
Figure 2 outlines the 173 tests on antihistamine patients
which reacted at zero on initial challenge following placebo. Upon
retesting after antihistamine, 102 tests (59%) remained at the zero 
level. Fifty-one tests rose to one plus, fourteen to two plus, and 
six to three plus, a total of 41% of the repeated tests showing a 
tendency to increase under antihistamine effect.
In Figure 2a, the zero reactors of the control or no-drug 
group are shown. Of the forty-two fcero tests on initial studies, 
thirty (71%) were also zero on second testing. Ten tests increased 
to one plus and two to three plus, for a total increase of 29%.
No tests reacted two plus or four plus.
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Figure 2. The zero reactions when retested following anti 
histamine could remain zero or increase. Note number of tests and 
per cent are presented.
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Figure 2a. Zero reactors in the control or no drug group.
Figure 3 details the tests which were initially one plus 
following placebo. Of the 163 in this group, seventy (43%) remained 
at the one plus reaction on retesting. Thirty-five tests fell to 
zero on retesting, a decrease of 217». On antihistamine, forty-one 
tests rose to two plus, twelve to three plus, and five to four plus, 
an increase of 36%.
Figure 3a includes fifty-five tests with an original reaction 
of one plus on no drug. Twenty-eight of the repeated tests remained 
at the one plus level, for a total of 51% unchanged. Sixteen of the 
repeated tests fell to zero,showing a total decrease of 29%. The 
20% which rose in reactivity consisted of nine tests which rose to 
two plus and two which rose to three plus.
Figure 4 illustrates 108 tests which reacted at the two plus 
level following placebo. Upon retesting following antihistamine, 
thirty-three (317o) remained two plus. Forty-four tests fell to one 
plus and nine fell to zero, a decrease of 49% of the tests when 
repeated under Pyribenzamine effect. Seventeen tests rose to three 
plus and five to four plus, an increase of 207o.
Figure 4a reflects the forty-one two plus tests in the contro 
group. Upon retesting, fifteen (37%,) were unchanged. Seventeen fell 
to one plus and two to zero, a decrease of 467.. In the two plus con­
trol group, four tests rose to three plus and three to four plus on 
retesting, a total increase of 17%.
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Figure 3. One plus reactions following placebo could remain 0 
the same, increase, or decrease when challenged after antihistamine.
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Figure 3a. One plus reactions in the no drug control group 3
with second tests at the same, decreased, or increased levels of ^
reactivity.
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Figure 4. Two plus reactions on placebo with subsequent 
test reactions on antihistamine.
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Figure 4a. Two plus reactions in the no drug control group
with second tests at the same, decreased, or increased levels of
reactivity.
Figure 5 represents 107 three plus tests following placebo. 
Thirty-six (34%) remained at three plus on retesting after anti­
histamine. Thirty-four tests fell to two plus, twenty-two to one 
plus, and three to zero on retesting, for a 55% decrease on anti­
histamine. A total of twelve tests (11%) rose to four plus on 
retesting.
Figure 5a shows twenty-seven control tests which were 
initially three plus reactive. In this group, fourteen (52%) were 
unchanged on retesting. Seven tests fell to two plus and three to 
one plus, a decrease of 377o. Three tests rose to four plus, an 11% 
increase.
Figure 6 represents 110 tests following placebo which reacted 
four plus. Upon retesting under antihistamine effect, sixty-three 
(577.) were unchanged. Twenty-four tests fell to three plus, twenty 
to two plus, and three to one plus, a decrease of 437o.
Figure 6a depicts thirty-four tests on control subjects which 
initially reacted four plus. Twenty-three (67%) were unchanged on 
retesting. Eight fell to three plus, two to two plus, and one to 
one plus, for a total decrease of 33%.
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Figure 5. Three plus reactions on placebo with subsequent 
antihistamine test reactions.
22
PATIENTS RECEIVING SINGLE DRUG
50-i
40 -
30-
20-
10-
0 -»
3 +
^ IN C R E A S E  
■■DECREASE 
E i3  UNCHANGED
TOTAL CASES 27
0  I
12 3 4
CASES PERC ENT
Figure 5a. Three plus reactions in the no drug control
group with second tests at the same, decreased, or increased levels
of reactivity.
23
PATIENTS RECEIVING PLACEBO AND ANTIHISTAMINE
4 +
60
50-
40-
30-
20-
10-
0-
CS3 INCREASE 
■ ■  DECREASE 
CZZI UNCHANGED
TOTAL CASES 110
I 2 3
CASES PERCENT
Figure 6. The four plus reactions when retested following 
antihistamine could remain at four plus or decrease.
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Figure 6a. Four plus reactions in the control group.
CHAPTER IV
DISCUSSION
General trend seen in data. The variation seen when the 
group tests were analyzed at zero, one plus, and two plus reactions 
(Figures 2-4a, pages 13, 14, and 16-19) is quite similar in both the 
control patients and those who received both drugs. At the higher 
levels of reaction, three and four plus (Figures 5-6a, pages 21-24) 
there seems to be a greater tendency for the antihistamine to show 
some depression when compared to tests following placebo.
It is emphasized that the downward trend did not remain 
uniform in any individual patient, and one who showed a single test 
change from four plus on placebo to two plus on antihistamine fre­
quently had the opposite change on other tests. Thus, no patient 
showed a strong general trend for all or most of the four plus reac­
tions to decrease on antihistamines but demonstrated the character­
istic only occasionally. The exception is one case in whom the 
downward trend was uniform and in whom the antihistamine tests were 
all lower than the tests recorded following placebo.
A H  skin reactions do not offer good basis for study.
The zero reactions and the four plus reactions do not offer good 
test comparison, since the change in either of these groups can only 
be in one direction. These two categories have a tendency to balance 
each other but do not add to the individual analysis of the data
except by their weight in studying general trends. If further 
testing were to be done, it is felt that the two and three plus 
reactions might offer the best range for study since these can 
respond both upward and downward and offer the best basis for 
analysis of results. These reactions are the most sensitive to 
change.
Additional studies on selected drug forms. After collection 
and analysis of the data on the above groups of patients, several 
smaller groups were tested to study the possibility that results 
obtained were totally the chance of the technique employed. Five 
patients were challenged with wheals measuring 5 mm., and this group 
showed results similar to the seventy-five in the original study. 
Another six patients were given Pyribenzamine Lontabs to assess the 
possibility that blood levels had varied in the previous series.
This group also reacted in the same manner and degree as the 
original group.
Positive skin tests found in persons who had no allergic 
history. It is of interest to note that the reactions of the group 
of nine patients who had no atopic or personal allergic history 
revealed that three had highly positive intradermal reactions. These 
were nonreactive to the diluent and had several strongly positive 
four plus tests. Careful questioning upon reviewing test results 
failed to disclose any signs or symptoms of allergy.
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CHAPTER V
CONCLUSIONS
The general data imply that oral antihistamines at therapeutic 
doses do not interfere with the intradermal skin testing as clinically 
performed by the allergist. The slight downward trend in the three 
and four plus reactions suggests the need for further study in this 
group.
A second fact brought out by the study is that the skin 
testing procedure is reproducible well within the useful limits of 
biological variation. A significant number of patients had identical 
tests on repeated challenge.
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